Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Bone Care International (NasdaqNM:BCII)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider
Recent Events
Aug  6Earnings Announcement
Location
1600 Aspen Commons
Middleton, WI 53562
Phone: (608) 662-7800
Fax: (608) 662-7800
Employees (last reported count): 66
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 57%
·Institutional: 53% (123% of float)
(66 institutions)
·Net Inst. Buying: 201.0K shares (+2.65%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Bone Care International Inc. is a pharmaceutical company engaged in discovering, developing and commercializing improved vitamin D-hormone therapies to treat secondary hyperparathyroidism in patients with kidney, or renal disease, and osteoporosis, and other diseases including psoriasis and cancers of the prostate, breast and colon. The Company licensed its first product, Hectorol, in 1987 from the University of Wisconsin, a leading vitamin D research center. Hectorol, also known as doxercalciferol, is a vitamin D replacement therapy approved by the FDA in two formulations to treat secondary hyperparathyroidism in patients with end-stage renal disease, or ESRD. In April 2000, the Company obtained FDA approval for Hectorol Injection, and, in late August 2000, the Company began selling this intravenous product in the United States. The Company recently completed two Phase III trials for Hectorol Capsules to treat secondary hyperparathyroidism in pre-dialysis patients.
More from Market Guide: Expanded Business Description

Financial Summary
Bone Care International is engaged in discovering and developing improved D-hormone therapies for treating secondary hyperparathyroidism. For the nine months ended 3/31/01, revenues totalled $3.9 million, up from $265 thousand. Net loss fell 3% to $6.6 million. Revenues benefitted from increased Hectoral Injection sales. Lower losses also benefitted from an increase in average cash balances due to the sale of common stock.

Recent Earnings Announcement
For the 3 months ended 06/30/2001, revenues were 2,059; after tax earnings were -2,374. (Preliminary; reported in thousands of dollars.)

More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Richard Mazess, Ph.D., 61
Chairman, Acting Pres and CEO
--  
Robert Beckman, 46
CFO, VP-Fin., Director
--  
Charles Bishop, Ph.D., 49
Exec. VP, R&D, Director
$152K
Paul Peterson, 49
VP of Sales and Marketing
162K
Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:BCIIAs of 31-Aug-2001
Price and Volume
52-Week Low
on 21-Dec-2000
$13.00 
Recent Price$20.20 
52-Week High
on 10-Nov-2000
$30.25 
Beta0.34 
Daily Volume (3-month avg)23.9K
Daily Volume (10-day avg)14.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-11.7%
52-Week Change
relative to S&P500
+18.5%
Share-Related Items
Market Capitalization$281.5M
Shares Outstanding13.9M
Float6.00M
Dividends & Splits
Annual Dividendnone 
Last Split: 2 for 1 on 17-Nov-1997
Per-Share Data
Book Value (mrq*)$2.90 
Earnings (ttm)-$0.70 
Earnings (mrq)-$0.17 
Sales (ttm)$0.47 
Cash (mrq*)$1.00 
Valuation Ratios
Price/Book (mrq*)6.95 
Price/EarningsN/A 
Price/Sales (ttm)43.44 
Income Statements
Sales (ttm)$6.00M
EBITDA (ttm*)-$9.92M
Income available to common (ttm)-$9.01M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsJune 30
Most recent quarter
(fully updated)
31-Mar-2001
Most recent quarter
(flash earnings)
30-June-2001
Management Effectiveness
Return on Assets (ttm)-33.59%
Return on Equity (ttm)-35.59%
Financial Strength
Current Ratio (mrq*)12.46 
Debt/Equity (mrq*)0 
Total Cash (mrq)$1.84M
Short Interest
As of 8-Aug-2001
Shares Short278.0K
Percent of Float4.6%
Shares Short
(Prior Month)
249.0K
Short Ratio11.12 
Daily Volume25.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001, except mrq*/ttm* items as of 31-Mar-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.